Producer
Nippon Electric Glass (NEG)
Japanese specialty glass manufacturer. In December 2025 launched world's first mass production of pharmaceutical glass tubing using an all-electric melting furnace (90% CO₂ reduction, arsenic-free) at a new facility in Selangor, Malaysia. Targeting GLP-1 drug demand growth.
0
Inputs supplied
0
Goods downstream
1
Facilities
0
Stories
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Display Glass (LCD + OLED Substrates)
50%Pharmaceutical Glass Tubing (Growing)
30%Electronic Components Glass
20%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Capacity2025
In December 2025, Nippon Electric Glass launched the world's first mass production line for pharmaceutical glass tubing using an all-electric melting furnace — reducing CO₂ emissions by 90% versus conventional fossil-fuel furnaces — at a new facility in Selangor, Malaysia. The line produces arsenic-free borosilicate tubing and was explicitly designed to meet demand from the GLP-1 obesity/diabetes drug market, which grew prescriptions from 680K/month (Jan 2020) to 4.7M/month (May 2025).
Nippon Electric Glass Co., Ltd. ↗Did you know2023
NEG's glass manufacturing platform serves both display electronics and pharmaceutical drug delivery from the same fundamental specialty glass chemistry: (1) LCD/OLED display substrates — thin, ultra-flat glass with tight compositional purity requirements for electronic-grade applications; every flat panel TV and OLED smartphone display uses substrate glass from one of ~3 companies globally (Corning, AGC, NEG); (2) Pharmaceutical borosilicate glass tubing — from NEG's new Malaysia all-electric furnace; the glass tubes are drawn to dimensional specifications, then converted by vial manufacturers into the primary containers for injectable drugs. The technical requirements for display glass (ultra-flat surfaces, low defect density, controlled thermal expansion) and pharmaceutical glass (chemical durability, low extractables, dimensional precision) share the same underlying glass manufacturing expertise, despite serving completely different end markets and regulatory frameworks. NEG's Malaysia pharmaceutical glass investment explicitly targets GLP-1 drug glass cartridges for Ozempic/Wegovy-type drugs — positioning the same Japanese electronics glass company as a supply solution for the pharmaceutical industry's fastest-growing demand.
Nippon Electric Glass Co., Ltd. ↗Origin2025
Nippon Electric Glass (NEG) was founded in 1949 in Otsu, Shiga Prefecture — initially established by the newly postwar Japanese government-backed plan to develop domestic glass manufacturing for television cathode-ray tube (CRT) glass. CRT television glass (high-lead glass for radiation shielding in the display panel) required precision glass manufacturing not yet available in Japan at the time. NEG's CRT glass business made it the dominant Japanese TV glass manufacturer through the analog television era. When flat panel displays (LCD, then OLED) replaced CRTs, NEG pivoted to liquid crystal display substrate glass. In December 2025, NEG launched what it claims is the world's first mass production pharmaceutical glass tubing using an all-electric melting furnace at a new facility in Selangor, Malaysia. The all-electric process reduces CO2 emissions by approximately 90% compared to conventional gas-fired furnaces AND eliminates arsenic (a traditional glass fining agent) from pharmaceutical glass — addressing both environmental and pharmaceutical safety requirements. A Japanese television glass company's technology pivot to electric furnace pharmaceutical glass in Malaysia serves the GLP-1 obesity drug cartridge market.
Nippon Electric Glass Co., Ltd. ↗